YOUR BUSINESS AUTHORITY

Springfield, MO

Home
Digital Edition
Events
Industries
Opinion
Podcasts
Photo Galleries
News Features
Sponsored Content

Log in Subscribe

Neurocrine Biosciences to acquire ⁠Soleno Therapeutics

Posted online April 6, 2026 | 7:54 am

Neurocrine Biosciences has entered a deal to purchase ⁠Soleno Therapeutics.

The deal is valued at $2.9 billion in cash.

Neurocrine Biosciences is reportedly expanding into metabolic disorders with the purchase.

Read more from CNBC.

Comments

No comments on this story |

Please log in to add your comment

More from SBJ Daily Update

Springfield's Vib hotel changes name

Editors' Pick

Costs mount as timeline extends on Historic City Hall

Hidden problems push completion to fall 2027, city manager reports.

Most Read

Piccolo announces closure

Springfield's Vib hotel changes name

Elon Musk plans to give a SpaceX share to every child in America

The Digital Edition from SBJ

Monday Morning Business Leads: Oct. 19, 2026

US steel prices surging

MSU honors Alex Riley for leadership, support

SBJ.net Poll

Councilmember Derek Lee proposed that Springfield develop a new coordinated plan to address homelessness. Do you think the city and local nonprofit efforts to address homelessness need a more coordinated approach?

*

Update cookies preferences